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Multidisciplinary Functional MR Imaging
for Prostate Cancer
Various functional magnetic resonance (MR) imaging techniques are used for
evaluating prostate cancer including diffusion-weighted imaging, dynamic con-
trast-enhanced MR imaging, and MR spectroscopy. These techniques provide
unique information that is helpful to differentiate prostate cancer from non-cancer-
ous tissue and have been proven to improve the diagnostic performance of MRI
not only for cancer detection, but also for staging, post-treatment monitoring, and
guiding prostate biopsies. However, each functional MR imaging technique also
has inherent challenges. Therefore, in order to make accurate diagnoses, it is
important to comprehensively understand their advantages and limitations, histo-
logic background related with image findings, and their clinical relevance for eval-
uating prostate cancer. This article will review the basic principles and clinical sig-
nificance of functional MR imaging for evaluating prostate cancer.
agnetic resonance (MR) imaging has been accepted to be a primary
imaging modality for evaluating prostate cancer on the basis of its
excellent soft tissue resolution. Traditionally, conventional T2-weighted
imaging (T2WI) with the combined application of endorectal and phased-array coils
was considered to be the most accurate MR imaging technique for detection, localiza-
tion, and staging of prostate cancer. However, over the past few decades, investigators
have shown that T2WI has limited value when it comes to detecting cancer in the
central gland. In addition, post-treatment monitoring issues such as low signal intensity
(SI) on T2WI can result from many non-cancerous conditions as well as prostate
cancer (1, 2). In order to improve the diagnostic performance of MRI, investigators
have applied diffusion-weighted imaging (DWI), dynamic contrast-enhanced (DCE)
MRI, and MR spectroscopy (MRS) to cancer detection, staging, monitoring of
treatment effect, and guidance from prostate biopsy. Recently, the majority of basic
and clinical researches of prostate cancer are shifting to these functional MR imaging
techniques. In addition, many studies have demonstrated the superiority of functional
MR imaging over conventional anatomic imaging information (e.g., T2WI) in various
clinical trials. However, investigators have also noted the challenges of the various MR
techniques, which may lead to artifacts and misleading information. Therefore,
accurate diagnoses require a comprehensive understanding of the advantages and
limitations, histologic background related with image findings, and their clinical
relevance in relation to the evaluation of prostate cancer. This article will review the
basic principles, imaging protocols, and clinical significance of each functional MR
technique for prostate cancer evaluation while focusing on recent issues cited in the
literature. 
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MDiffusion-Weighted Imaging
Basic Principle 
Diffusion is the process of thermally-induced, or
Brownian, random motion of molecules and causes a signal
decay on DWI according to the degree of magnetization
dephasing by water motion between the two diffusion
gradients. Therefore, the degree of diffusion can be
expressed by the following equation: 
ADC = - (log SIα- log SI�)/(bα- b�)
where b is the diffusion weighting value (s/mm
2), SIαand SI�
are the SIs at the b-value of bαand b�, and apparent
diffusion coefficient (ADC) is the apparent diffusion coeffi-
cient (mm/s
2) (Fig. 1). 
The SI on DWI is principally influenced by T2 relaxation
(e.g., T2 shine-through effect), and diffusion. A low b-value
DWI is a greater contributing factor to T2 relaxation, and
therefore a high b-value is recommended for obtaining a
more accurate diffusion measurement. Moreover, to
eliminate the T2 shine-through effect, an ADC map should
be obtained with two or more b-values.
Another issue regarding the ADC is its possible contami-
nation by perfusion when a b-value of 0 s/mm
2 is used for
its calculation. According to Le Bihan et al. (3), the
measured ADC in vivo is often higher than expected due
to the effect of microcirculation through the capillaries
within a voxel. He suggested that the ADC be calculated
with two b-values greater than 0 s/mm
2 in order to
Kim et al.
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AB
Fig. 1. Diffusion-weighted imaging.
A, B. Diffusion-weighted imagings in regions of interest (arrows) with b-values of 0 s/mm
2 (A) and 1,000 s/mm
2 (B). 
C. Apparent diffusion coefficient map.
D. Logarithmic-scale signal intensity of diffusion-weighted imagings plotted against b-values. Signal intensities in region of interest
(arrows in A-C) are 1,412 a.u. with b-value of 0 s/mm
2 and 186 a.u. as well as with b-value of 1,000 s/mm
2. Therefore, apparent diffusion
coefficient is 2.027 × 10
-3 mm/s
2.
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5.5eliminate this perfusion effect (3, 4) (Fig. 2). 
Classically, the attenuation of SI on DWI, with respect to
an increasing b-value, has been known to follow a
monoexponential pattern. However, more recent findings
have identified a biexponential characterization of water
diffusion decay curves over an extended b-factor range in
the prostate (5), which has already been observed in the
brain. The authors suggested a new equation as follows:
SI = (Afast exp[-ADCfast b] + Aslow exp[-ADCslow b]),
where SI is the SI at a certain b-value; SI0 is the SI at a b-
value of 0 s/mm
2; b is the b-value; Afast and Aslow are the
apparent amplitudes of the fast and slow component; and
ADCfast and ADCslow are the fast and slow ADCs, respec-
tively.
Histological Background for Application of Diffusion-
Weighted Imaging to Prostate Disease
The diffusion property in the tissue is determined by the
distribution of water molecules between extracellular and
intracellular spaces. Extracellular water has a greater range
of diffusion than intracellular water because diffusion of
water is more restricted by membranes or other cellular
structures in the intracellular space (6, 7). The prostate is
an organ containing an abundance of glandular tissue with
extracellular spaces. In contrast, prostate cancer shows
decreased diffusion since it has abundant inter- and intra-
cellular membranes, a high cell density, substantial cellular
edema, and elevating interstitial pressure due to the loss of
ATP-dependent sodium-potassium pumps (1, 8). These
histological characteristics result in different diffusion
properties when comparing a normal gland to cancer tissue
in the prostate. 
Similar to prostate cancer, non-cancerous tissue of the
prostate has various diffusion properties according to its
various tissue composition types. A benign prostatic
hyperplasia (BPH) gives rise to inhomogeneous diffusion
patterns as it changes the distribution of cellular density.
Whereas, BPH-related increased cellular density decreases
the diffusion of the central gland, which is usually less
predominant than prostate cancer but may mimic prostate
cancer (9, 10). Prostatitis may also change the diffusion
properties of the prostate as it causes increased interstitial
pressure and the aggregation of various inflammatory cells.
As these histological changes tend to restrict diffusion,
prostatitis can cause high SI on DWI, as well as decreased
ADC, thereby mimicking prostate cancer (11). 
Even in normal prostate tissue, the ADC is significantly
higher in the peripheral zone , which has abundant glandu-
lar tissue (12), compared to the transitional or central
zones (10, 13) due to the fact that prostate tissue in the
transitional and central zones have more compact stroma
and more longitudinally arranged smooth muscle than in
the peripheral zone tissue. Moreover, SI on DWI and the
ADC may change with increasing age due to atrophy in
Multidisciplinary Functional MR Imaging for Prostate Cancer
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AB
Fig. 2. Effect of b-values on apparent diffusion coefficient.
A. Region of interest (arrow) drawn on diffusion-weighted imaging.
B. Logarithmic-scale signal intensity of diffusion-weighted imaging plotted against b-values (0, 125, 250, 500, 750, 1,000 mm
2/s) used to
acquire diffusion-weighted imaging. Logarithmic-scale signal intensity at y-axis is plotted against b-value at x-axis. Each datum point in
plot is denoted by two numbers: logarithmic-scale signal intensity, original signal intensity. Different apparent diffusion coefficient values
were computed by different pairs of b-values: 4.78 × 10
-3 mm/s
2 with b-values of 0 and 125 mm
2/s, as well as 1.41 × 10
-3 mm/s
2 with b-
values of 125, 250, 500, 750 and 1,000 mm
2/s. Apparent diffusion coefficient value was higher with pair of lower b-values because of
increased contributions from perfusion effects.
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Table 1. Mean ± ± SD (× × 10
-3 mm
2/s) ADC Values of Prostate in Normal and Cancer Subjects Reported in Various Studies
Authors Subject and Coil Type
Non-Cancer  Non-Cancer Cancer Cancer b-value 
PZ TZ PZ TZ (seconds/mm
2)
Kim et al. 47 cancer patient  1.57 ± 0.18 1.44 ± 0.31 0.99 ± 0.21 0.96 ± 0.14 2 values 
(10) (endorectal coil) (0 and 1,000)
Kim et al. 37 cancer patients  1.96 ± 0.20 1.75 ± 0.23 1.30 ± 0.26 1.35 ± 0.24 2 values 
(13)  (3T, phased array coil) (0 and 1,000)
Sato et al. 23 cancer patients 1.80 ± 0.41 1.58 ± 0.37 1.08 ± 0.39 1.13 ± 0.42 2 values 
(15) (pelvic coil) (300 and 600)
Issa et al. 19 cancer patients 1.82 ± 0.53 1.62 ± 0.41 1.38 ± 0.52 6 values 
(16) (pelvic coil) (64, 144, 257, 401, 578, 786)
Note.─ PZ = peripheral zone, TZ = transitional zone, SD = standard deviation, ADC = apparent diffusion coefficient 
Fig. 3. Apparent diffusion coefficient values in various regions of prostate.
A. Gross pathological image of radical prostatectomy specimen. Prostate cancer is marked with outline.
B-D. Apparent diffusion coefficient map (B), diffusion-weighted imaging (C) and T2-weighted imaging (D) corresponding to A. Prostate
cancer (arrows) shows low signal intensity on apparent diffusion coefficient map and high signal intensity on diffusion-weighted imaging.
Prostate cancer is clearly identified on apparent diffusion coefficient map and diffusion-weighted imaging, whereas T2-weighted imaging
shows lower lesion conspicuity. Prostate cancer is outlined in A. Apparent diffusion coefficients are 0.95 × 10
-3 mm/s
2 in prostate cancer,
1.02 × 10
-3 mm/s
2 in non-cancerous transitional zone tissue (black circle in B), and 1.14 × 10
-3 mm/s
2 in non-cancerous peripheral zone
tissue (white circle in B). 
CD
ABthe prostate, which leads to reduced cell volume and
enlarged glandular ducts (14). 
Apparent Diffusion Coefficients between Prostate
Cancer and Non-Cancerous Tissue
It is widely known that the ADC is lower in prostate
cancer than in non-cancerous tissue. Moreover, when the
ADC was compared in non-cancerous tissue based on its
anatomic location, the transitional zone or central gland
showed a lower ADC than the peripheral zone (10, 12, 15,
16) (Fig. 3) (Table 1). Recently, Kim et al. (10) reported
that the ADC was significantly lower in the prostatic base
than in the transitional and peripheral zones, and
suggested that the lower ADC in the prostatic base was
caused by a significantly lower ADC in the central zone. 
Despite the tendency of different ADC values in prostate
cancer and non-cancerous tissue, studies have also shown a
significant overlap of the ADC values between prostate
cancer and non-cancerous tissue, which is attributed to the
fact that the ADC varies widely in both prostate cancer
and non-cancerous tissue (Figs. 4, 5). This overlap of the
ADC limits the accuracy of DWI in cancer detection. This
overlap seems to be prominent between both prostate
cancer and non-cancerous transitional zone tissue because
it has a lower ADC than peripheral zone tissue (10, 16-
18). Therefore, a higher diagnostic accuracy based on a
region-of-interest analysis in previous studies might be
exaggerated, and the actual diagnostic accuracy for cancer
detection may not be as satisfactory as expected in clinical
practice. 
Imaging Techniques 
Recently, single shot echo planar imaging (EPI) has been
most widely used for DWI. Since EPI is vulnerable to
distortion and artifacts in areas with magnetic susceptibil-
ity, such as air-tissue interfaces or chemical-shift effect in
fat-water interfaces, fat suppression is mandatory.
The types of coil used seems to vary by study; some
studies used endorectal coils, while others used pelvic
phased-array coils. An endorectal coil provides a superior
signal-to-noise ratio (SNR) but causes reduced patient
compliance and increased susceptibility effects. Whereas,
the pelvic phased-array coil results in a relatively inferior
SNR, which may be overcome by increasing the number of
averages used in imaging; however, the compensatory
strategy results in a longer image acquisition time (19). 
Diffusion-weighted imaging is likely to perform better
with a 3T, as opposed to a 1.5T system, since a 3T system
provides greater SNR as well as a greater spatial and
temporal resolution. Since an endorectal coil is available
with a 3T system, the combination of a phased-array and
endorectal coil can be used for prostate DWI, which
Multidisciplinary Functional MR Imaging for Prostate Cancer
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Fig. 4. Distribution of apparent diffusion coefficient in non-cancer-
ous tissue on color-coded apparent diffusion coefficient map.
Scale of color display ranges from 0.5 × 10
-3 mm/s
2 (black) to 2.2
× 10
-3 mm/s
2 (red). Apparent diffusion coefficient of non-cancer-
ous tissue ranges from 0.84 × 10
-3 mm/s
2 to 2.2 × 10
-3 mm/s
2.
Table 2. Comparison of Diagnostic Performance for Cancer Detection between T2WI Alone and Combination of T2WI and DWI
Authors
T2WI T2WI + DWI
Sensitivity (%) Specificity (%) Accuracy (%) Sensitivity (%) Specificity (%) Accuracy (%)
Lim et al. (9) * 74 79 77 88 88 88
Kim et al. (13) 66 NS NS 84 NS NS
Haider et al. (22) 54 91 77 81 84 83
Tanimoto et al. (23) 73 54 64 84 85 84
Morgan et al. (24) * 50 80 67 73 81 78
Tamada et al. (25) 
� 51 91 75 69 85 78
Note.─ * These data are those of experienced one among readers. 
� This study considered 12-core-systemic biopsy as reference standard for MRI detection of prostate cancer and dynamic contrast-enhanced MRI is
included for detection prostate cancer. 
T2WI = T2-weighted imaging, DWI = diffusion-weighted imaging, NS = not specifiedaccording to some authors, provides an improvement in
the image quality for DWI (8, 19). A higher sensitivity to
susceptibility is a potential drawback of a high field system.
The sensitivity can be reduced by applying parallel imaging
techniques, which in turn decrease echo spacing and echo
train length (19).
Clinical Significance: Advantages and Challenges
Advantages ─ DWI demonstrates a high SI for prostate
cancer compared to normal prostate tissue. Also, a
decrease in diffusion for prostate cancer shows a low signal
on an ADC map (Fig. 3). Prostate cancer appears more
conspicuous on DWI or an ADC map than for conven-
tional T2WI. Since DWI requires a short scan time, it can
be used as an adjunct to standard MR imaging for the
identification and localization of prostate cancer and can
improve the diagnostic performance of MRI for cancer
detection. Recent studies have evaluated the diagnostic
ability of prostate cancer detection per se (9, 13, 20-23).
Many studies showed a significantly improved diagnostic
accuracy when combining DWI and T2WI compared to
T2WI alone (9, 13, 22-25) (Fig. 3) (Table 2).
Consequently, it seems to make sense to combine DWI
and T2WI, since DWI can be readily acquired as a part of
standard clinical prostate MR protocol rather a replace-
ment of the conventional T2WI.
Kim et al.
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Fig. 6. Road map for prostate biopsy.
A. T2-weighted imaging of prostate from
59-year-old man with elevated prostate-
specific antigen levels (13.5 ng/ml) and
prior negative biopsy result. 
B. Corresponding apparent diffusion
coefficient map. Two lesions (arrows) in
transitional zone show low signal
intensity on apparent diffusion coeffi-
cient map, whereas they are not clearly
identified on T2-weighted imaging.
Targeted biopsy of these lesions was
performed under transrectal ultrasonog-
raphy-guide in which, two lesions were
confirmed to be prostate cancer.
AB
AB
Fig. 5. Distribution of apparent diffusion coefficient on color-coded apparent diffusion coefficient map in 62-year-old patient with prostate
cancer. 
A. Gross pathological image of radical prostatectomy specimen. Prostate cancer is marked with black line.
B. Corresponding apparent diffusion coefficient map. Scale of color display ranges from 0.5 × 10
-3 mm/s
2 (black) to 1.8 × 10
-3 mm/s
2
(red). Apparent diffusion coefficient of prostate cancer ranges from 0.59 × 10
-3 mm/s
2 to 1.8 × 10
-3 mm/s
2.High lesion conspicuity on DWI and ADC maps can help
the introduction of an image-guided biopsy in patients with
previous negative biopsy results and elevated serum
prostate-specific antigen (PSA) levels (11, 26) (Fig. 6).
According to Park et al. (26), prostate cancer was detected
in 17 of 43 patients (40%) with a previously negative
biopsy. Moreover, the location of the unidentified cancer
on the previous biopsy was more common in the transi-
tional zone (76%) than in the peripheral zone (24%). In
addition to tumor detection, high lesion conspicuity on DWI
can improve the diagnostic accuracy for prostate cancer
staging. According to Kim et al. (27), the combination of
DWI and T2WI showed a better diagnostic performance
than T2WI alone for predicting seminal vesicle invasion.
For example, the area-under-curve (AUC) for T3b was
0.815 for T2WI with DWI and 0.696 for T2WI alone. 
Challenges ─ A significant overlap exists for the ADC
values between prostate cancer and non-cancerous tissue
as well as heterogeneous ADC values according to zonal
anatomy, and also the presence of non-cancerous
conditions that decrease diffusion, such as BPH and prosta-
titis. These represent the main challenges for the applica-
tion of DWI and ADC maps in prostate cancer detection
(10) (Fig. 7). Gibbs et al. (28) reported that quantitative T2
mapping and DWI of the prostate central gland showed no
Multidisciplinary Functional MR Imaging for Prostate Cancer
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Fig. 7. T2-weighted imaging (A) and apparent diffusion coefficient map (B) of prostate from 61-year-old man with elevated prostate-
specific antigen levels (10.6 ng/ml). Lesion (arrows) in transitional zone shows low signal intensity on both T2-weighted imaging and
apparent diffusion coefficient map. Targeted biopsy of this lesion was performed under transrectal ultrasonography-guide, but no cancer
was identified.
AB
Fig. 8. Time-intensity curves of prostate cancer (A) and non-cancerous tissue (B). Compared to non-cancerous tissue, prostate cancer
tissue shows early and strong enhancement as well as rapid de-enhancement. 
AB
TA = 21
Time to Peak = 92
Data not used
Data used
Fitting Curve = Brix-model
Brix-model
0 50 100 150
450
400
350
300
250
200
150
100
50
0 50 100 150
time, s
I
n
t
e
n
s
i
t
y
Brix-model
TA = 28
Time to Peak = 34
Data not used
Data used
Fitting Curve = Brix-model
400
350
300
250
200
150
100
50
I
n
t
e
n
s
i
t
y
time, sstatistical difference when comparing the T2 value and the
mean ADC between BPH and prostate cancer. They
postulated that morphological changes of BPH
subsequently cause changes in the tissue structure that can
affect the properties of water diffusion. These structural
changes can lead to inaccurate ADC measurements in the
transitional zone and false positive results on DWI. Haider
et al. (22) demonstrated that, even with combined DWI
and T2WI, the accuracy of detection for prostate cancer
was lower in the transitional zone (AUC, 0.78) than in the
peripheral zone (0.89). 
Another factor which likely affected the diagnostic value
of DWI was the subjective interpretations of individual
radiologists. One study reported substantial interobserver
agreement (Kappa value, 0.73) for the diagnosis of seminal
vesicle invasion by DWI and T2WI (27), while another
study showed only a fair interobserver agreement (Kappa
value, 0.51) for cancer detection by ADC and T2WI (24).
Moreover, other studies have demonstrated that more
experienced observers achieve a greater diagnostic
accuracy for cancer detection or staging by DWI compared
to less-experienced observers (9, 24, 27).  
Dynamic Contrast-Enhanced MRI
Basic Principle and Histologic Background
The theoretical background of DCE MRI is strongly
related with tumor angiogenesis. Angiogenesis is an
inevitable requirement for growth beyond a 2 mm
diameter, invasion to other organs, and distant metastasis
in malignant neoplasms (4). As a result of angiogenesis, the
number of vessels and permeability through the vascular
wall increases significantly. Furthermore, since cancer
tissue has larger interstitial space than normal tissue, it
correspondingly shows a greater difference in the concen-
tration of intravenous (IV) contrast material between
intravascular and extravascular spaces. In turn; this
marked difference in concentration accelerates the contrast
transfer through the vascular wall. This characteristic
environment results in a unique enhancement pattern for
cancer on DCE MRI (e.g., early strong enhancement and
rapid de-enhancement) (1, 29, 30) (Fig. 8).
Vascular endothelial growth factor plays a key role in
tumor angiogenesis and is also the case for prostate cancer
(29, 31). Jackson et al. (32) detected vascular endothelial
growth factor in tumor cells and peritumoral stromal cells
of prostate cancer specimens. Therefore, prostate cancer is
an appropriate disease for evaluating the tumor angiogene-
sis on DCE MRI.
Time Intensity Curve and Tracer Kinetic Models
Several perfusion-related parameters can be extracted
from a time-intensity curve and tracer kinetic models of
DCE MRI data (30, 33-39); although, software for analyz-
ing a time-intensity curve is widely available whereas,
tracer kinetic models are not commercially released and
only applicable on a research basis. 
The analysis of a time-intensity curve is only applicable
for simple datasets when determining the shape of the
curve, whereas tracer kinetic models allow for more highly
sophisticated parameters with respect to tumor perfusion,
such as permeability (flux of contrast material between
intravascular and interstitial spaces), area of intravascular
Kim et al.
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Fig. 9. Schematic drawing of two compartment model. IV contrast
material, when administrated, exists in two compartments such
as intravascular space and extravascular (interstitial) spaces. In
addition, IV contrast material transfer between these two
compartments is dependent on difference of concentration
between two compartments.
Fig. 10. Dynamic contrast-enhanced MR image of 68-year-old
male patient with prostate cancer. K
trans, Ve, initial upslope, Kep,
peak enhancement, and wash-out are 0.091/s, 0.137, 30/s,
0.77/s, 350 a.u., and -1.34/s in prostate cancer (double arrows),
and 0.018/s, 0.100, 19/s, 0.12/s, 150 a.u., and 0.78/s in non-
cancerous tissue (arrow), respectively.
Transfer of contrast
material depending on
concentration gradient
Artery
Vein
Intravascular space
(plasma)
Extravascular
extracellular space
(Interstitial space)space, and area of interstitial space. Although various trace
kinetic models have been introduced, they share the same
theoretical background (37): a) IV contrast material, when
administered, exists in two compartments, i.e. intravascu-
lar space and extravascular (interstitial) space (Fig. 9), b) IV
contrast material transfer between these two compart-
ments is dependent on a concentration gradient, c) time
variation (e.g., the parameters describing the compart-
ment) is constant during the time that data are obtained,
and d) relaxivity (1/T1) after IV contrast material injection
is proportional to the concentration of IV contrast material
according to the following equation: 
1/T1 = 1/T10 + R1∙Ct
whereas Ct is the tissue concentration of the tracer, R1 is
the relaxivity of the tracer, and T10 is the native T1 (i.e.,
the value of T1 before injection of tracer).
The most widely used tracer kinetic model for evaluating
angiogenesis on DCE MRI is the Tofts model. This model
extracts the concentration of contrast material in the
plasma (Cp), which is derived from arterial input function,
fractional volumes of the extravascular extracellular space
(Ve) and plasma (Vp), as well as the permeability through
the blood vessels (K
trans). 
Similarly, the Brix model has been also used for DCE
MRI. The premise of this model assumes that a linear
correlation exists between SI and the concentration of IV
contrast material. Originally, SI does not follow this
suggestion, but this assumption is allowed when the
concentration of IV contrast material is very low. The Brix
model also extracts the flux from the extravascular
extracellular space (Kep), elimination rate of contrast
material from the plasma (Kel), and amplitude constant
(A
H). 
In the Tofts model, Kep is similar to K
trans/Ve and A
H
corresponds to the volume of the extravascular extracellu-
lar space. The most unique characteristic of the Tofts
model is that there is no need to measure arterial input
function, which determines the Cp. Moreover, the arterial
input function may be unreliable according to measure-
ment and thereby may change the value of parameters.
Based on these principles, investigators suggested various
tracer kinetic models (37-39). The perfusion-related
parameters from various tracer kinetic models are
summarized in Table 3. 
Imaging Techniques 
Although there has been no consensus regarding the
imaging acquisition protocol for DCE MRI of the prostate,
there is a general recommendation that has been recently
published by the National Cancer Institute and can be
accessed online (40) (Table 4). According to this
recommendation, a gradient-echo sequence would be
adequate for image acquisition since it is fast and can cover
the entire prostate within 5 seconds. It is, unless contra-
Multidisciplinary Functional MR Imaging for Prostate Cancer
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Table 4. Recommendations for MRI Measurements of Tumor Vascular Function
Item Methods
Pre-injection  1. If possible, measure T1 (using same resolution and field of view for dynamic data) 
2. Acquire maximum spatial resolution image (determined by application) 
Contrast agent injection  1. If possible, use power injector to minimize variation 
2. 15-30 sec for total injection, saline flush 
Dynamic study  1. If possible, sample arterial input function 
2. For first 90-150 sec after bolus injection, use 10-30 sec temporal resolution (fastest sampling
possible consistent with spatial resolution requirements) 
Table 3. Comparison of Three Two-Compartment Models
Tofts and Kermode Model Larsson Model Brix Model
Plasma concentration Assumed normal (bi-exponential) Measured from blood samples Fitted with single rate constant
Estimated parameters K
trans, Ve, Vp Kep  Kep, A
H, Kel
Measurement of T10 Yes Not necessarily No
Measurement of R10 Yes No No
Note.─ K
trans in Tofts and Kermode model, meaning contrast flux between intravascular and extravascular extracellular space. Ve = fractional volume 
of extravascular extracellular (interstitial) space, Vp = fractional volume of intravascular space, Kep = K
trans/Ve, in Larsson model, and Kep K21 = Kep in Brix
model, meaning contrast flux from extravascular extracellular space to intravascular space, Kel = contrast elimination rate from plasma, A
H = fractional
volume of interstitial space in Brix modelindicated, recommended to suppress the peristalsis of the
bowels by administrating a anti-peristaltic agent, such as
butylscopolamine, for preventing the movement of the
prostate during imaging acquisition. The author’s protocol
involving a 3T scanner is as follows: 3D acquisition of
gradient sequence; repetition time/echo time, 3.3/1.6 msec;
flip angle of 10� ; slice thickness, 4 mm; no interslice gap;
field of view, 180 mm; matrix size, 64 × 64; and the
number of slices, 20. With this protocol, the time resolu-
tion of each dynamic set is 3 seconds and 150 sequences
are obtained in each patient. 
Clinical Significance: Advantages and Challenges
Advantages ─ Investigators have found that many
parameters from DCE MRI are different between prostate
cancer and non-cancerous tissue, including the K
trans, Ve,
initial upslope, Kep, area under a time-intensity curve, peak
enhancement, and wash-out rate (30, 33, 35, 36, 41) (Fig.
10). Although it seems to be difficult to coordinate the
various results of previous studies, they can be translated
as the comparison between prostate cancer and non-
cancerous tissue showing that cancer tissue has a high
permeability and wide extravascular space, which leads to
early strong enhancement and rapid de-enhancement.
With unique perfusion evident in prostate cancer, studies
have also shown that DCE MRI is helpful for the detection
and localization of prostate cancer (11, 13, 25, 30, 41, 42)
(Table 5). Moreover, based on an improved capacity for
cancer detection, DCE MRI has been shown to provide a
high accuracy for determining the extracapsular extension
of prostate cancer (34, 43) (Fig. 11). According to Bloch et
al. (34), the sensitivity, specificity, positive predictive
value, and negative predictive value for the assessment of
extracapsular extension for DCE MRI and T2WI was 86%,
Kim et al.
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Table 5. Various Parameters for Detection and Localization of Prostate Cancer on DCE MRI
Authors Parameter(s) Location Sensitivity (%) Specificity (%) Accuracy (%)
Tamada (25) Focal early enhancing area (1 min) Entire prostate 46 93 74
Kim et al. (30) Wash-in rate Entire prostate 96 82 88
PZ 96 97 97
TZ 96 51 72
Fu ¨tterer et al.  Wash-out Entire prostate 69 96 90
(33) * Ve Entire prostate 95 88 90
Kep Entire prostate 85 88 87
K
trans Entire prostate 87 87 87
Kim (41) Hyperintense area (1 min) PZ 73 77 75
Note.─ * These data are those of experienced one among readers. 
DCE = dynamic contrast-enhanced, PZ = peripheral zone, TZ = transitional zone
Fig. 11. T2-weighted imaging (A) and Kep map (B) of 59-year-old male patient with prostate cancer (arrows). On T2-weighted imaging,
extracapsular extension of prostate cancer is not clearly identified. Kep map shows cancer focus in peripheral zone of right lobe.
According to T2-weighted imaging and Kep map, extracapsular extension was suggested. Pathologic finding confirmed extracapsular
extension in same site.
AB95%, 90%, and 93%, respectively. Moreover, the sensitiv-
ity for the determination of the extracapsular extension
with T2WI could be improved by more than 25% after
combining it with DCE MRI. Recently, in addition to
cancer detection and staging, researchers have postulated
that DCE MRI is feasible and useful for monitoring the
efficacy of both surgical and non-surgical treatments.
According to Casciani et al. (44), DCE MRI showed a
higher sensitivity (88%) and specificity (100%) for detect-
ing local recurrence after a radical prostatectomy
compared to performing an endorectal MRI alone (sensitiv-
ity, 48%; specificity, 52%). Whereas, all tumor recurrence
showed signal enhancement on DCE MRI and 91% of
recurring tumors showed rapid and early signal enhance-
ment. Haider et al. (45) reported that an irregular margin
of tumor on DCE MRI suggests the effect of the vascular
targeted treatment, and Kim et al. (46) reported that the
combination of DCE MRI and DWI showed a greater
accuracy for diagnosing tumor recurrence after radiother-
apy upon the discovery of a significantly greater AUC for
combined DCE MRI and DWI (AUC, 0.863) compared to
T2WI, DCE MRI, and DWI alone. 
Challenges ─ ─ Despite promising results by previous
investigators with regard to using various perfusion
parameters from DCE MRI for cancer detection and
localization, it should be noted that those parameters also
showed considerable overlap between prostate cancer and
non-cancerous tissue (30, 36, 47). This limitation is
prominent for differentiating prostate cancer from non-
cancerous transitional zone tissue. This overlap also
decreases specificity for cancer detection, as noted in
previous studies (specificity of 51%) (30) (Fig. 12). This
limitation is caused by increased BPH angiogenesis, which
was indicated by a significant overlap of the microvessel
density between BPH and prostate cancer (48). 
Another challenge with DCE MRI is that there are too
many parameters for observers to interpret. Indeed, it is
difficult to make a single decision by comprehensively
evaluating all parameters. Recently, investigators have
attempted to formulate a single predictor for detecting
prostate cancer on the basis of a comprehensive analysis of
the various perfusion parameters. Ocak et al. (49)
developed a predictor by using a generalized-estimating-
equations/logistic regression model, which comprehen-
sively analyzed K
trans, Kep, Ve, area of time-intensity curve,
and the interpretation of T2WI. The sensitivity and
specificity of the computer-aided diagnosis (CAD) system
was 80% and 75%, respectively. Vos et al. (50) developed
a CAD system using a support vector machine and
included T1, Kep, K
trans, Ve, and late wash-out. The AUC for
differentiating prostate cancer from non-cancerous tissue in
the peripheral zone was 0.83, which was substantial. 
Lastly, the enhancement pattern on DCE MRI may be
variable since it depends on various factors including
patient age, cardiovascular status, temporal resolution of
MR imaging, and tissue perfusion. Therefore, since the
threshold of each perfusion parameter for differentiating
cancer from non-cancerous tissue may also vary, it
becomes difficult to designate a threshold for cancer
detection. 
MR Spectroscopy
Imaging Technique
The most widely accepted technique for prostate MRS is
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Fig. 12. Transitional zone versus prostate cancer.
A. Gross pathological image of radical prostatectomy specimen located where area of prostate cancer is outlined. 
B. K
trans map shows increased perfusion in transitional and peripheral zones of right lobe. Multiple foci of high permeability areas in transi-
tional zone are related with benign prostatic hyperplasia rather than prostate cancer.
ABKim et al.
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Fig. 14. Images of 62-year-old man with prostate cancer. Although prostate cancer is not clearly identified on T2-weighted imaging, MR
spectroscopy shows increased choline and creatine (double arrows) over citrate (arrow) ratio in voxels 2, 3, 6 and 7, which were
confirmed to be prostate cancer. 
Fig. 13. Spectroscopy in prostate cancer.
A. Typical spectrum of prostate cancer, where choline peak (double arrows) is increased and citrate peak (arrow) is decreased.
B. Typical spectrum of non-cancerous tissue, which shows high citrate peak (arrow), as well as triplet on 3T MR spectroscopy.
ABchemical shift imaging with point resolved spectroscopy
(PRESS) voxel excitation and band selective inversion with
gradient dephasing for water and lipid suppression (1, 33,
51). This technique produces a cubic voxel by acquisition
of three orthogonal slice selective pulses, the volume of
which can be less than 0.24 mL. MRS and T2WI are
usually obtained simultaneously, thereby providing the
metabolic map overlaid on an anatomical display.  
Histologic Background
Prostate cancer detection and localization on MRS are
based on the different metabolic rates of cancer and non-
cancerous tissue. The abundant citrate-producing metabo-
lism of a normal gland is replaced by a citrate-oxidating
metabolism in prostate cancer (1, 2). The level of choline in
cancer simultaneously increases because of a high turnover
of phospholipid in cell membranes in the proliferating
tissue. This metabolic shift in prostate cancer leads to the
elevation of the choline/citrate ratio (2) (Fig. 13). Because
of the proximity of the choline and creatine peaks
observed by MRS, which was performed with a clinical MR
scanner, the ratio of choline and creatine to citrate, which
also is increased in prostate cancer, is the parameter of
choice.
Clinical Significance: Advantages and Challenges
Advantages ─ Many previous studies have demonstrated
that MRS improves the detection and localization of
prostate cancer. According to Kurhanewicz et al. (52),
choline and creatine to citrate ratio was at least 2 standard
deviations greater for the cancer region in the peripheral
zone, compared with the normal peripheral zone. Males et
al. (53) showed that voxels with a ratio of choline and
creatine to citrate greater than 3 standard deviations above
the average ratio were very suggestive of cancer.
According to Scheidler et al. (54), although the sensitivity
and specificity for cancer detection were 77% and 61%
(reader 1) and 81% and 46% (reader 2) for T2WI alone, as
well as 63% and 75% for MRS alone, the specificity for
the combination of MRS and MR imaging was 95%. A
high level of sensitivity (up to 95%) was obtained when
either test alone indicated a positive result (Fig. 14). 
The combined use of MR imaging and MRS may be
useful in evaluating low-risk prostate cancer. According to
Shukla-Dave et al. (55), the combined use of T2WI and
MRS was better at predicting the probability of insignifi-
cant prostate cancer (pathologically defined as organ
confined tumor 0.5 cm
3 or less in volume with no element
of Gleason grade 4 or 5 cancer), compared to clinical
models using preoperative clinical variables (clinical stage,
serum PSA level) and/or biopsy data. These results may
help to prevent some patients with clinically insignificant
cancer to be over-treated.  
Like DWI and DCE MRI, a prostate biopsy guided by
MRS may raise the cancer detection rate in patients with
elevated PSA levels and a previous negative biopsy result
Multidisciplinary Functional MR Imaging for Prostate Cancer
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Fig. 15. MR spectra (A, B) in single voxel. Ratio of choline and creatine over citrate changes after post-processing.
AB(56). Moreover, MRS can be used to predict the aggressive-
ness of the prostate cancer. Investigators observed that the
ratio of choline and creatine to citrate and tumor volume
correlated with the pathologic Gleason score (57).
Challenges ─ The major limitations of MRS are long
acquisition time, inter-observer variable interpretation by
postprocessing or shimming, and no direct visualization of
the periprostatic anatomy (Fig. 15).
In addition, a previous biopsy leading to hemorrhage
may cause field inhomogeneity, which causes spectral
degradation and renders the interpretation of the metabo-
lite ratios inaccurate. According to Qayyum et al. (58), the
mean percentage of degraded peripheral-zone voxels was
19% for a MRS performed within eight weeks of a biopsy,
compared to 7% for a MRS performed greater than eight
weeks after a biopsy. 
In recent years, the authors suggested that MRS is more
sensitive than conventional MR imaging for detecting
transitional zone cancer (59). Nevertheless, the cancer
metabolite ratio in the transitional zone ranges so widely
that the metabolite ratios overlap significantly for cancer-
ous and non-cancerous tissues in the transitional zone.
Clinical Application
Imaging Acquisition Protocol ─ To date no standard-
ized protocol for imaging acquisition has been established,
particularly for the time resolution of DCE MRI, b-values
for DWI, application of endorectal coil, and the external
magnetization of the MR unit (1.5T or 3T). Our MRI
examination is performed using a pelvic phased-array coil
at a 3T unit, including T2WI, T1WI, DCE MRI, and DWI
for the prostate and body (Table 6). With this protocol, the
actual scanning time is approximately 40 minutes and one
session for the entire examination requires approximately
50 minutes. The ADC map from the DWI and permeabil-
ity map (Kep) as well as the time to peak map from DCE
MRI is generated by in-house software, which are
displayed on a workstation. DWI for the body is displayed
in a reverse mode, which is used for detecting metastatic
lymph nodes or bone metastasis. At our institution, due to
the limited scanning time allowed for each patient, the
MRS is only obtained in patients who have specific indica-
tions, such as clinical research or discordant findings
between DCE MRI and DWI. For MRS, additional 10 to 15
minutes are required. To obtain the optimal image
protocol, rectal peristalsis and the amount of rectal gas
should be reduced. Rectal peristalsis may affect the
interpretation of DCE MRI because the location of prostate
changes by peristalsis and a large amount of rectal gas
causes local field inhomogeneity, thereby leading to image
distortion on DWI and spectral degradation on MRS.
Therefore, at our institution, patients are requested to
evacuate, and then intravenous hyoscine butyl bromide
(20 mg) is injected prior to MR examination. 
Finally, a comprehensive interpretation of the spin-echo
images and functional MR images is a difficult task for
radiologists and therefore, we recommend the same slice
thickness and inter-slice gap for all images in order to
reduce the burden for anatomical correlation between the
various images.
Interpretation ─ A biopsy-related hemorrhage causes
field inhomogeneity, leading to image distortion on DWI
and spectral degradation on MRS. Hemorrhage may also
Kim et al.
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Table 6. MR Image Acquisition Parameters at 3 Tesla in Asan Medical Center
Sequence T2WI (FSE) T1WI (FSE) DWI DCE MRI Body DWI
Imaging plane Axial, coronal and sagittal Axial Axial Axial Axial
Coils Phased-array Phased-array Phased-array Phased-array Phased-array
Anatomic coverage Aortic bifurcation to pubic symphysis (T2WI~DCE MRI) Kidney to pubic symphysis
TE (msec) 80 10 56 1.6 55
TR (mesc) 4,100-4,200 530-550 3,200-3,300 3.3 8,000
Slice thickness 4 4 4 4 4
FOV (cm) 18 18 18 18 36
Matrix 256×256 256×256 80×80 64×64 88×88
Number of average 3 2 6 2 1
Echo train length 16 4
Acquisition time (min) 10.5 3-4  5-6  7-8  10-12 
Flip angle (。 )9 0 9 0 9 0 1 0
b-values (s/mm
2) 0, 125, 250, 500, 750, 1,000 0, 1000
Note.─ FSE = fast spine echo, DWI = diffusion-weighted imaging, DCE MRI = dynamic contrast-enhanced MRI, TE = repetition time, TR = echo time, 
FOV = field of view. Body DWI is displayed in reversed mode. affect the measurement of perfusion parameters when
using the Tofts model because the T1 value, which is
mandatory for calculating perfusion parameters, may be
influenced by hemorrhage. Unfortunately, there is no
method to reduce the effect of hemorrhage, its effect,
which is shown to be a high SI on T1WI, should be consid-
ered when interpreting functional MR images.
Although prostate cancer detection and localization are
definitely improved using functional MR images, because
the spatial resolution or SNR are limited in functional
images, T2WI is necessary for determining the local
staging, particularly for the diagnosis of extracapsular
extension. Most previous studies also showed the best
diagnostic performance when combining the functional
images and T2WI.
Despite markedly improving cancer detection and
localization by functional MR images, limitations still exist
to accurately differentiate between cancer and non-cancer-
ous tissue in the transitional zone. Therefore, when
interpreting the preoperative MR images for prostate
cancer, the number and location of positive specimens
from ultrasonography-guided biopsy, Gleason score, and
serum PSA level should be also considered as these
parameters are related with the tumor volume. 
Although recent studies have shown the value of
functional MRI for guiding a targeted biopsy in patients
with previously negative biopsy results and elevated serum
PSA levels, a systemic randomized biopsy cannot be
replaced with a targeted biopsy because of mis-registration
between the MRI and ultrasonographic images, which is a
potential limitation of MRI for the detection of small
prostate cancer, and a lack of an open magnet MR machine
for MR-guided biopsy.
Future Directions ─ Since various functional MR
techniques were introduced in clinical practice, prostate
cancer detection and localization has markedly improved.
Based on various biological parameters, functional MR
techniques are anticipated to help monitor the non-surgical
treatment responses of prostate cancer as well as guiding
the intensity of local treatment. To extend the role of
functional MR techniques in evaluating prostate cancer, the
reliability of measuring parameters for each technique and
the standardization of image acquisition protocol should be
established.
Summary
Diffusion-weighted imaging, DCE MRI and MRS are
currently available functional MR techniques and have
been proven to be valuable for improving the diagnostic
performance of MRI as a tool for evaluating the incidence
of prostate cancer. To establish an accurate interpretation,
it is essential that one understands the advantages and
limitations of each technique.
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